Source comparison
Stacking Strategies: Synergy vs Receptor Saturation
Not all peptide combinations are equal. The difference between a synergistic stack and a wasteful one comes down to receptor pathway mapping. MK-677 occupies ghrelin receptors continuously. Pairing it with another ghrelin agonist (GHRP-2, GHRP-6, hexarelin) cr
This comparison does not assign a generated winner or score.
- Not all peptide combinations are equal. The difference between a synergistic stack and a wasteful one comes down to receptor pathway mapping. MK-677 occupies ghrelin receptors continuously. Pairing it with another ghrelin agonist (GHRP-2, GHRP-6, hexarelin) creates competition for the same binding sites. Both compounds vie for GHS-R1a occupancy, neither achieves full receptor activation, and somatostatin feedback kicks in earlier than it would with single-compound protocols.
- Synergistic combinations exploit different pathways. The most validated stack in research literature pairs MK-677 with CJC-1295 Ipamorelin. MK-677 activates ghrelin receptors while CJC-1295 activates GHRH receptors, creating dual-pathway GH stimulation without receptor competition. A 2021 comparative trial published in the Journal of Endocrinology found this combination produced 2.3× greater IGF-1 elevation than either compound alone at equivalent doses, with no increase in cortisol or prolactin spillover.
- Timing matters as much as compound selection. Short-acting GHRPs like ipamorelin have a half-life of approximately 2 hours. Dosing them 4–6 hours after your daily MK-677 dose allows ghrelin receptor occupancy to cycle down before the next stimulation pulse. This preserves the amplitude of each GH pulse rather than creating a blunted, sustained elevation. Researchers using this staggered approach consistently report higher peak GH values on ELISA testing compared to simultaneous dosing of both compounds. We've found that timing windows matter more than most protocol guides acknowledge. Dose too close together, and you lose pulse definition entirely.